

AMENDMENTS

In the Claims

The following listing of claims replaces all previous listings or versions thereof:

1-6. (Canceled)

7. (Previously presented) A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising administering to the patient an antibody to protein C in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma.

8. (Previously presented) The method of claim 7 further comprising the step of topically administering a coagulant at the site of bleeding.

9. (Previously presented) The method of claim 8 wherein the topically administered coagulant is selected from the group consisting of thrombin in a dosage of between approximately 1000 and 10,000 units and tissue factor in a dosage of between approximately 0.1 and 10 mg.

10-19. (Canceled)

20. (Previously presented) A method for inhibiting microvascular bleeding at a site in a patient exhibiting microvascular bleeding comprising systemically administering to the patient a monoclonal antibody to protein C which blocks protein C activation in a pharmaceutically acceptable carrier in an effective amount to prevent anticoagulation by greater than 90% of activated protein C in human plasma.

21. (Currently amended) The method of claim 20 wherein the antibody is HPC-4, deposited with the American Type Culture Collection, ~~Rockville MD~~ Manassas, VA and assigned ATCC No. 9892.